MORRISVILLE, N.C.--(BUSINESS WIRE)--Phase Bioscience, Inc., (PhaseBioTM) a development stage biotechnology company, announced today that it has secured worldwide, exclusive rights to several issued patents relevant to key aspects in the therapeutic use of elastin-like polypeptide (ELP) technology. Collectively, these patents are known as the “Urry Portfolio.”
